The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Nanolongan with Multiple On-Demand Conversions for Ferroptosis–Apoptosis Combined Anticancer Therapy
Open accessAbstract
As a type of programmed cell death, ferroptosis is distinct from apoptosis. The combination of the two thus provides a promising modality with which to significantly improve anticancer treatment efficacy. To fully utilize this combination, we herein designed a nanolongan delivery system, which possessed a typical structure of one core (up-conversion nanoparticles, UCNP) in one gel particle (Fe 3+ cross-linked oxidized starch) with multiple on-demand conversions. The charge conversion of the nanolongan surface in a slightly acidic microenvironment enhanced circulation time for utilizing the enhanced permeability and retention effect, enabled efficient uptake by tumor cells, and induced subsequently lysosomal escape. As the core component, the UCNP with light conversion from near-infrared light to ultraviolet light circumvented the impediment of limited penetration depth and enabled the reduction of Fe 3+ to Fe 2+ . Accordingly, gel networks of nanolongan could be deconstructed due to this valence conversion, leading to the rapid release of Fe 2+ and doxorubicin (Dox). In this case, the Fenton reaction between Fe 2+ and intracellular H 2 O 2 generated potent reactive oxygen species for ferroptosis, while the co-released Dox penetrated into nucleus and induced apoptosis in a synergistic way. As a result, superior anticancer therapeutic effects were achieved with little systemic toxicity, indicating that our nanolongan could serve as a safe and high-performance platform for ferroptosis–apoptosis combined anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Identification of ACSL4 as a biomarker and contributor of ferroptosis
Yuan, H., Li, X., Zhang, X., Kang, R., & Tang, D. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.124 · Cited by 1,071
T cell lipid peroxidation induces ferroptosis and prevents immunity to infection
Matsushita, M., Freigang, S., Schneider, C., Conrad, M., Bornkamm, G. W., & Kopf, M. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140857 · Cited by 672
Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90118-x · Cited by 409
Pratt, D. A., Tallman, K. A., & Porter, N. A. (2011) · Accounts of Chemical Research · doi:10.1021/ar200024c · Cited by 352
Cited by
Recent Progress in Ferroptosis Inducers for Cancer Therapy
Liang, C., Zhang, X., Yang, M., & Dong, X. (2019) · Advanced Materials · doi:10.1002/adma.201904197 · Cited by 1,569
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
Biomedicine Meets Fenton Chemistry
Tang, Z., Zhao, P., Wang, H., Liu, Y., & Bu, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00977 · Cited by 745
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Jiang, Y., Zhao, X., Huang, J., Li, J., Upputuri, P. K., Sun, H., Han, X., Pramanik, M., Miao, Y., Duan, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15730-x · Cited by 433
He, Y.-J., Liu, X.-Y., Xing, L., Wan, X., Chang, X., & Jiang, H.-L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119911 · Cited by 318
Self-citationWan, X., Song, L., Pan, W., Zhong, H., Li, N., & Tang, B. (2020) · ACS Nano · doi:10.1021/acsnano.9b07789 · Cited by 305
Recent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
Strategies for enhancing cancer chemodynamic therapy performance
Jana, D., & Zhao, Y. (2022) · Exploration · doi:10.1002/exp.20210238 · Cited by 284
Xu, W., Qian, J., Hou, G., Wang, T., Wang, J., Wang, Y., Yang, L., Cui, X., & Suo, A. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202205013 · Cited by 267
Yu, B., Choi, B., Li, W., & Kim, D.-H. (2020) · Nature Communications · doi:10.1038/s41467-020-17380-5 · Cited by 262
Metadata
- Authors
- Bao, W., Liu, X., Lv, Y., Lu, G.-H., Li, F., Zhang, F., Liu, B., Li, D., Wei, W., & Li, Y.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-01-07
- Volume
- 13
- Issue
- 1
- Pages
- 260-273
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2906870968
- Cited by
- 206
- References
- 9
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.